March 2023 in “The Journal of Urology” Nocturia cases increased, but medication use declined, suggesting under-treatment.
March 2023 in “The Journal of Urology” The MTOPS trial investigated the effect of finasteride, doxazosin, or their combination on urinary symptoms in men with benign prostatic hyperplasia (BPH). Analysis of prostate biopsies and clinical data from 82 participants revealed that higher expression of SRD5A2, an enzyme regulated epigenetically, was associated with a better response to finasteride treatment. Specifically, men with higher SRD5A2 expression showed greater improvement in urinary symptoms, as measured by the AUA symptom score. This finding suggests that SRD5A2 expression could be a predictor of response to finasteride, potentially aiding in the development of precision medicine approaches for BPH treatment.
April 2022 in “Urology Practice” Early intervention for acute urinary retention can reduce costs and improve care.
April 2022 in “The Journal of Urology” Men may experience long-term sexual dysfunction after stopping Finasteride.
20 citations,
April 2023 in “The Journal of Urology” PRP is safe but not more effective than a placebo for treating mild to moderate erectile dysfunction.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
20 citations,
October 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
14 citations,
May 2016 in “Therapeutic advances in urology” Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
8 citations,
August 2021 in “Fertility and Sterility” Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
2 citations,
January 2023 in “Sexual Medicine” The Men's Training Cup Keep Training masturbation aid may help delay ejaculation and improve erectile function.
January 2024 in “Saudi pharmaceutical journal” The study successfully formulated and optimized a bilayer tablet combining Tamsulosin and Finasteride using response surface methodology.
November 2023 in “The Journal of Urology” The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
May 2023 in “Brazilian Journal of Health Review” The study aimed to evaluate the pharmacokinetic profile and bioequivalence of a fixed combination tablet containing finasteride (5 mg) and doxazosin (2 mg) compared to the individual administration of these drugs. Conducted as a randomized, crossover study with 30 subjects, the results showed no significant differences in the pharmacokinetic parameters (AUC0-72h, AUC0-∞, and Cmax) between the combination tablet and the single agents. The mean ratios of AUC0-72h/AUC0-∞ for finasteride and doxazosin were nearly 100%, indicating adequate sampling time and confirming bioequivalence. This suggests that the combination tablet does not alter the pharmacokinetics of the individual drugs, supporting its use in clinical practice.
March 2014 in “Hair transplant forum international” Hair transplant surgeons should also focus on their patients' overall health, including regular check-ups and screening for common health issues.
19 citations,
February 2018 in “The Journal of urology/The journal of urology” Poor sleep is linked to a higher risk of developing and worsening urinary problems in men.
1 citations,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
September 2012 in “African Journal of Urology” Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.
40 citations,
November 2020 in “JAMA Dermatology” Finasteride may cause suicidal thoughts and mental side effects, especially in young people with hair loss.
19 citations,
February 2012 in “International Journal of Urology” In Japan, sex reassignment surgery for gender identity disorder faces challenges and needs better medical support and education.
April 2010 in “The Journal of Urology” Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.
31 citations,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
26 citations,
August 2014 in “PubMed” Testosterone improves mood and thinking skills; finasteride has no effect.
17 citations,
May 2021 in “Journal of Assisted Reproduction and Genetics” COVID-19 may harm male fertility and damage the reproductive system.
October 2020 in “System Dynamics Review” The document concludes that finasteride can reduce nandrolone detection in doping tests, suggesting frequent testing and setting metabolite level thresholds for detection.
August 2023 in “IntechOpen eBooks” Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.
July 2023 in “IntechOpen eBooks” Hair loss can significantly impact a person's mental health, causing issues like anxiety and depression, and stress can trigger hair loss.
July 2023 in “IntechOpen eBooks” Some types of hair loss can be reversed, others are permanent, and treatments vary by type.
3 citations,
September 2014 in “Journal of obstetrics and gynaecology Canada” Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.
16 citations,
May 2013 in “Urology” Metabolic syndrome linked to urinary symptoms; hair loss not significant.
4 citations,
November 2017 in “Cancer Causes & Control” Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.